Transforming Anabolic Treatments for Osteoporosis: New Clinical Data Supports a Single EB613 Tablet [Oral PTH(1-34)] as the Final Candidate for a Phase 3 Study

Jun 14, 2026 from 4:30 PM to 5:30 PM EDT

Late-Breaking Oral Abstract/Rapid-Fire II

Supporting Materials